000 | 01920 a2200529 4500 | ||
---|---|---|---|
005 | 20250514000716.0 | ||
264 | 0 | _c20010614 | |
008 | 200106s 0 0 eng d | ||
022 | _a0022-3565 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPonnappa, B C | |
245 | 0 | 0 |
_aIn vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. _h[electronic resource] |
260 |
_bThe Journal of pharmacology and experimental therapeutics _cJun 2001 |
||
300 |
_a1129-36 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aChemical and Drug Induced Liver Injury |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
650 | 0 | 4 | _aDrug Stability |
650 | 0 | 4 | _aEndosomes |
650 | 0 | 4 | _aHydrogen-Ion Concentration |
650 | 0 | 4 | _aIn Vitro Techniques |
650 | 0 | 4 | _aInjections, Intravenous |
650 | 0 | 4 |
_aLipopolysaccharides _xpharmacology |
650 | 0 | 4 | _aLiposomes |
650 | 0 | 4 |
_aLiver _xdrug effects |
650 | 0 | 4 |
_aLiver Diseases _xmetabolism |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aOligonucleotides, Antisense _xadministration & dosage |
650 | 0 | 4 |
_aOrganothiophosphorus Compounds _xadministration & dosage |
650 | 0 | 4 | _aPhosphorothioate Oligonucleotides |
650 | 0 | 4 |
_aRNA, Messenger _xantagonists & inhibitors |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Sprague-Dawley |
650 | 0 | 4 |
_aSpleen _xmetabolism |
650 | 0 | 4 | _aTissue Distribution |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
700 | 1 | _aDey, I | |
700 | 1 | _aTu , G C | |
700 | 1 | _aZhou, F | |
700 | 1 | _aAini, M | |
700 | 1 | _aCao , Q N | |
700 | 1 | _aIsrael, Y | |
773 | 0 |
_tThe Journal of pharmacology and experimental therapeutics _gvol. 297 _gno. 3 _gp. 1129-36 |
|
999 |
_c11289081 _d11289081 |